REG - EKF Diagnostics Hldg - Notice of Interim Results & Investor Presentation

EKF Diagnostics HoldingsAnnouncement

01/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220901:nRSA8308Xa&default-theme=true

RNS Number : 8308X  EKF Diagnostics Holdings PLC  01 September 2022

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Notice of Interim Results & Investor Presentation

 

Notice of Results

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, confirms that the Company will announce its interim results for the
six months ended 30 June 2022 on Tuesday 20 September 2022.

 

Investor Presentation

Mike Salter, Chief Executive Officer, and Marc Davies, Chief Financial
Officer, will be hosting a live online presentation relating to the interim
results via the Investor Meet Company platform at 4.30 pm on Tuesday 20
September 2022. The presentation is open to all existing and potential
investors.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation
here: https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
(https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor)

 

Investors who already follow EKF on the Investor Meet Company platform will
automatically be invited.

 

Questions can be submitted pre-event via your IMC dashboard or in real time
during the presentation, via the "Ask a Question" function. Whilst the
Company may not be in a position to answer every question it receives, it will
address the most prominent within the confines of information already
disclosed to the market through regulatory notifications. A recording of the
presentation, a PDF of the slides used, and responses to the Q&A session
will be available on the Investor Meet Company platform afterwards.

 

 

 EKF Diagnostics Holdings plc                                   www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Mike Salter, CEO / Marc Davies, CFO                             Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Joint Broker)      Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas

 Investec Bank plc (Joint Broker)                               Tel: +44 (0)20 7597 4000
 Gary Clarence / Daniel Adams / Ben Farrow

 Walbrook PR Limited                                            Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth                               Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

EKF is a leading global diagnostics business with custom manufacturing
facilities across sites in the US, UK and Europe for a variety of life science
products. EKF is focussed on the following areas:

 

 Point-of-Care           Providing a portfolio of Point-of-Care analysers and consumables, particularly
                         for use in the area of Hematology and Diabetes, for use in hospital and
                         research laboratories, doctor's offices, blood banks and for in-field anaemia
                         screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit,
                         HbA1c, glucose and lactate analysers in regular use across more than 100
                         countries.

 Central Laboratory      Clinical chemistry, Small lab analysers, Centrifuges

                         Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin, Glycated Serum
                         Protein, Nitro-tab, Procalcitonin

 Life Sciences           Enzyme fermentation, Custom products and Bulk fermentation

 Contract Manufacturing  Bulk formulation, Sample collection kits, Private labelling, Molecular and
                         forensic kits

 Laboratory Services     In September 2021, EKF completed the acquisition of Advanced Diagnostic
                         Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified
                         under the Clinical Laboratory Improvement Amendments ("CLIA") for high
                         complexity testing. The laboratory provides testing for a variety of clinical,
                         forensic and microbiological sample types using a range of analytical
                         techniques. This acquisition positions EKF as a leading 'one stop' provider of
                         diagnostic products and services from sample collection to results.

 

EKF's growth strategy to 2024 and beyond can be summarised as:

 •    continuing innovation in products and services in Point-of-Care, Central
      Laboratory and Life Sciences leveraging new and existing routes to market and
      relationships;
 •    investment in expanded production and kitting capabilities to offer a suite of
      diagnostic Contract Manufacturing solutions to third party businesses;
 •    expansion of CLIA Laboratories Testing offering, building on the acquired
      capabilities in ADL Health; and
 •    concluding complementary earnings-enhancing acquisitions with key strategic
      value.

 

EKF will also continue to generate enhanced shareholder value through:

 •    a progressive dividend policy; and
 •    its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us
      advanced access to innovative commercial opportunities such as those already
      seen with Renalytix plc, Verici Dx plc and Trellus Health plc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREAKPFDADAEFA